Noevir Holdings Co., Ltd. (4928) AI Stock Analysis

• Market Cap: ¥157.97B
• Dividend Yield: 4.86%
• Average Volume (3M): 56.08K
• Price to Earnings (P/E): 20.8
• Beta (1Y): 0.42
• Revenue Growth: -1.63%
• EPS Growth: 1.81%
• Country: JP
• Employees: 1,369
• Sector: Consumer Defensive
• Sector Strength: 57
• Industry: Household & Personal Products
• EPS (TTM): 43.39
• Shares Outstanding: 34,156,624
• 10 Day Avg. Volume: 68,690
• 30 Day Avg. Volume: 56,083
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ¥4,798.00
• Price Target Upside: 3.74% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

• Rating: 74 Outperform
• Price Target: ¥4,798.00 ▲(3.74% Upside)

Noevir Holdings Co., Ltd. demonstrates strong financial performance with robust profitability and a solid balance sheet. The valuation is appealing, driven by a reasonable P/E ratio and a high dividend yield. Technical indicators show mixed signals, with potential short-term weakness but also signs of being oversold, which could offer buying opportunities. The absence of recent earnings call data or notable corporate events results in these components not influencing the score.

Noevir Holdings Co., Ltd. Business Overview & Revenue Model

Company Description

Noevir Holdings Co., Ltd. is a Japanese company that operates primarily in the beauty and health sectors. The company is known for developing, manufacturing, and selling a wide range of cosmetics, skincare products, and health-related goods. Noevir's offerings cater to both individual consumers and professional markets, with a focus on high-quality, innovative personal care solutions. Additionally, the company is involved in the pharmaceuticals and nutritional supplements sectors, providing a diversified portfolio of products that promote overall well-being.

How the Company Makes Money

Noevir Holdings Co., Ltd. generates revenue primarily through the sale of its cosmetics and skincare products, which are distributed via direct sales channels, retail stores, and online platforms. The company's revenue model is supported by a strong network of sales representatives and partnerships with retail chains. Additionally, Noevir benefits from its presence in the health care and nutritional supplements markets, where it sells various products aimed at enhancing health and wellness. The company also engages in research and development to continually innovate its product offerings, thereby maintaining a competitive edge in the beauty and health industries.

Noevir Holdings Co., Ltd. Financial Statement Overview

Summary

Noevir Holdings Co., Ltd. presents a strong financial profile with consistent profitability and a robust balance sheet. Revenue and profit margins are solid, while leverage remains low, indicating financial prudence. However, cash flow generation shows some decline, which, although still sufficient, could affect future investment capacity. Monitoring cash flow trends will be crucial for sustaining financial health.

Income Statement

The income statement reveals a positive trajectory with stable revenue growth, evidenced by a 2.3% increase in revenue from the previous year. The gross profit margin remains strong at 67.06% for TTM, and the net profit margin is healthy at 12.48%. EBIT and EBITDA margins indicate efficient operations with EBIT at 17.08% and EBITDA at 19.04%. While the company shows consistent profitability, slight fluctuations in EBIT suggest some operational cost pressures.

Balance Sheet

The balance sheet shows a robust financial position with a low debt-to-equity ratio of 0.02, reflecting minimal leverage. The equity ratio is strong at 66.45%, indicating substantial equity financing. Return on equity stands at 16.59%, demonstrating effective use of equity to generate profits. Overall, the balance sheet highlights financial stability, though the slight decrease in stockholders' equity warrants monitoring.

Cash Flow

Cash flow analysis shows a decrease in operating cash flow year-over-year, with a TTM free cash flow growth rate of -37.36%. The operating cash flow to net income ratio is 0.86, while the free cash flow to net income ratio is 0.63, suggesting adequate conversion of net income into free cash flow. Despite some decline in free cash flow, the company maintains sufficient liquidity to support its operations.

Breakdown	Sep 2024	Sep 2023	Sep 2022	Sep 2021	Sep 2020
Income Statement
Total Revenue	63.82B	62.55B	61.14B	51.27B	51.84B
Gross Profit	43.16B	42.56B	42.09B	33.03B	33.08B
EBITDA	12.44B	12.24B	11.57B	10.05B	9.76B
Net Income	7.97B	7.67B	7.59B	6.38B	5.62B
Balance Sheet
Total Assets	76.47B	77.25B	76.78B	80.45B	80.05B
Cash, Cash Equivalents and Short-Term Investments	29.22B	28.88B	29.75B	31.10B	29.46B
Total Debt	828.00M	914.00M	1.00B	1.11B	1.22B
Total Liabilities	22.57B	24.04B	24.40B	28.22B	27.81B
Stockholders Equity	53.48B	52.79B	52.05B	51.93B	51.98B
Cash Flow
Free Cash Flow	8.11B	6.57B	5.23B	8.63B	5.67B
Operating Cash Flow	9.12B	7.62B	5.84B	9.06B	7.31B
Investing Cash Flow	1.52B	-3.54B	-255.00M	-416.00M	-1.61B
Financing Cash Flow	-7.71B	-7.49B	-7.38B	-7.18B	-6.96B

Noevir Holdings Co., Ltd. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 4625.00
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4928, the sentiment is Positive. The current price of 4625 is above the 20-day moving average (MA) of 4611.25, above the 50-day MA of 4439.10, and above the 200-day MA of 4502.27, indicating a bullish trend. The MACD of 76.15 indicates Positive momentum. The RSI at 57.13 is Neutral, neither overbought nor oversold. The STOCH value of 32.32 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:4928.

Noevir Holdings Co., Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
4928	74 Outperform	¥157.97B	20.78		4.86%	-1.63%	1.81%
4927	70 Neutral	¥289.70B	45.07	3.99%	3.97%	-0.89%	-34.14%
4912	66 Neutral	$441.98B	21.57	7.29%	1.78%	1.29%	4.72%
4967	64 Neutral	¥402.71B	34.21	5.72%	1.90%	-6.64%	-13.78%
Sector *	63 Neutral	$20.97B	14.57	-8.07%	3.14%	2.79%	-9.97%
4922	60 Neutral	$331.06B	110.54	1.11%	2.41%	2.82%	-79.45%
4911	58 Neutral	¥1.01T	496.62		1.99%	-3.60%	-112.93%

Noevir Holdings Co., Ltd. Corporate Events

Noevir Holdings Reports Decline in Nine-Month Financial Results

Noevir Holdings Co., Ltd. reported a decline in its financial performance for the first nine months of the fiscal year ending September 30, 2025, with net sales and operating income both experiencing decreases compared to the previous year. Despite the downturn, the company maintains its dividend forecast and anticipates slight growth in net sales and income for the full fiscal year, suggesting a cautious optimism in its future operations.